Production of IL-1β by bone marrow-derived macrophages in response to chemotherapeutic drugs

References

• Schwartz AL, Nail LM, Chen S, Meek P, Barsevick AM, King ME, Jones LS. Fatigue patterns observed in patients receiving chemotherapy and radiotherapy. Cancer Invest 2000; 18:11 - 9; http://dx.doi.org/10.3109/07357900009023057; PMID: 10701362
   PubMed Web of Science ®Google Scholar
• Glaus A, Crow R, Hammond S. A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals. Support Care Cancer 1996; 4:82 - 96; http://dx.doi.org/10.1007/BF01845757; PMID: 8673356
   PubMed Web of Science ®Google Scholar
• Irvine D, Vincent L, Graydon JE, Bubela N, Thompson L. The prevalence and correlates of fatigue in patients receiving treatment with chemotherapy and radiotherapy. A comparison with the fatigue experienced by healthy individuals. Cancer Nurs 1994; 17:367 - 78; http://dx.doi.org/10.1097/00002820-199410000-00001; PMID: 7954384
   PubMed Web of Science ®Google Scholar
• Jacobsen PB, Hann DM, Azzarello LM, Horton J, Balducci L, Lyman GH. Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symptom Manage 1999; 18:233 - 42; http://dx.doi.org/10.1016/S0885-3924(99)00082-2; PMID: 10534963
   PubMed Web of Science ®Google Scholar
• Nail LM, Winningham ML. Fatigue and weakness in cancer patients: the symptoms experience. Semin Oncol Nurs 1995; 11:272 - 8; http://dx.doi.org/10.1016/S0749-2081(05)80008-7; PMID: 8578035
   PubMedGoogle Scholar
• Dodd MJ, Miaskowski C, Lee KA. Occurrence of symptom clusters. J Natl Cancer Inst Monogr 2004; 76 - 8; http://dx.doi.org/10.1093/jncimonographs/lgh008; PMID: 15263044
   PubMedGoogle Scholar
• Wood LJ, Weymann K. Inflammation and neural signaling: etiologic mechanisms of the cancer treatment-related symptom cluster. Curr Opin Support Palliat Care 2013; 7:54 - 9; http://dx.doi.org/10.1097/SPC.0b013e32835dabe3; PMID: 23314015
   PubMedGoogle Scholar
• Bower JE, Lamkin DM. Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications. Brain Behav Immun 2013; 30:Suppl S48 - 57; http://dx.doi.org/10.1016/j.bbi.2012.06.011; PMID: 22776268
   PubMed Web of Science ®Google Scholar
• Jassar AS, Suzuki E, Kapoor V, Sun J, Silverberg MB, Cheung L, Burdick MD, Strieter RM, Ching LM, Kaiser LR, et al. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Cancer Res 2005; 65:11752 - 61; http://dx.doi.org/10.1158/0008-5472.CAN-05-1658; PMID: 16357188
   PubMed Web of Science ®Google Scholar
• Kriegler AB, Bernardo D, Verschoor SM. Protection of murine bone marrow by dexamethasone during cytotoxic chemotherapy. Blood 1994; 83:65 - 71; PMID: 8274755
   PubMed Web of Science ®Google Scholar
• Logan RM, Stringer AM, Bowen JM, Yeoh AS, Gibson RJ, Sonis ST, Keefe DM. The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev 2007; 33:448 - 60; http://dx.doi.org/10.1016/j.ctrv.2007.03.001; PMID: 17507164
   PubMed Web of Science ®Google Scholar
• Tannenbaum CS, Wicker N, Armstrong D, Tubbs R, Finke J, Bukowski RM, Hamilton TA. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J Immunol 1996; 156:693 - 9; PMID: 8543822
   PubMed Web of Science ®Google Scholar
• Wood LJ, Nail LM, Perrin NA, Elsea CR, Fischer A, Druker BJ. The cancer chemotherapy drug etoposide (VP-16) induces proinflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy-related symptoms. Biol Res Nurs 2006; 8:157 - 69; http://dx.doi.org/10.1177/1099800406290932; PMID: 17003255
   PubMed Web of Science ®Google Scholar
• Elsea CR, Roberts DA, Druker BJ, Wood LJ. Inhibition of p38 MAPK suppresses inflammatory cytokine induction by etoposide, 5-fluorouracil, and doxorubicin without affecting tumoricidal activity. PLoS One 2008; 3:e2355; http://dx.doi.org/10.1371/journal.pone.0002355; PMID: 18523641
   PubMed Web of Science ®Google Scholar
• White CM, Martin BK, Lee LF, Haskill JS, Ting JP. Effects of paclitaxel on cytokine synthesis by unprimed human monocytes, T lymphocytes, and breast cancer cells. Cancer Immunol Immunother 1998; 46:104 - 12; http://dx.doi.org/10.1007/s002620050468; PMID: 9558006
   PubMed Web of Science ®Google Scholar
• Sodhi A, Pai K. Increased production of interleukin-1 and tumor necrosis factor by human monocytes treated in vitro with cisplatin or other biological response modifiers. Immunol Lett 1992; 34:183 - 8; http://dx.doi.org/10.1016/0165-2478(92)90211-6; PMID: 1487305
   PubMed Web of Science ®Google Scholar
• Schubert C, Hong S, Natarajan L, Mills PJ, Dimsdale JE. The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav Immun 2007; 21:413 - 27; http://dx.doi.org/10.1016/j.bbi.2006.11.004; PMID: 17178209
   PubMed Web of Science ®Google Scholar
• Cheung YT, Lim SR, Ho HK, Chan A. Cytokines as mediators of chemotherapy-associated cognitive changes: current evidence, limitations and directions for future research. PLoS One 2013; 8:e81234; http://dx.doi.org/10.1371/journal.pone.0081234; PMID: 24339912
   PubMed Web of Science ®Google Scholar
• Wang XS, Williams LA, Krishnan S, Liao Z, Liu P, Mao L, Shi Q, Mobley GM, Woodruff JF, Cleeland CS. Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain Behav Immun 2012; 26:699 - 705; http://dx.doi.org/10.1016/j.bbi.2011.12.007; PMID: 22251605
   PubMed Web of Science ®Google Scholar
• Smith LB, Leo MC, Anderson C, Wright TJ, Weymann KB, Wood LJ. The role of IL-1β and TNF-α signaling in the genesis of cancer treatment related symptoms (CTRS): a study using cytokine receptor-deficient mice. Brain Behav Immun 2014; 38:66 - 76; http://dx.doi.org/10.1016/j.bbi.2013.12.022; PMID: 24412646
   PubMed Web of Science ®Google Scholar
• Ganz PA, Bower JE, Kwan L, Castellon SA, Silverman DH, Geist C, Breen EC, Irwin MR, Cole SW. Does tumor necrosis factor-alpha (TNF-α) play a role in post-chemotherapy cerebral dysfunction?. Brain Behav Immun 2013; 30:Suppl S99 - 108; http://dx.doi.org/10.1016/j.bbi.2012.07.015; PMID: 22884417
   PubMed Web of Science ®Google Scholar
• Vodopivec DM, Rubio JE, Fornoni A, Lenz O. An unusual presentation of tumor lysis syndrome in a patient with advanced gastric adenocarcinoma: case report and literature review. Case Rep Med 2012; 2012:468452; http://dx.doi.org/10.1155/2012/468452; PMID: 22685470
   PubMedGoogle Scholar
• Delbaldo C, Michiels S, Syz N, Soria JC, Le Chevalier T, Pignon JP. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004; 292:470 - 84; http://dx.doi.org/10.1001/jama.292.4.470; PMID: 15280345
   PubMed Web of Science ®Google Scholar
• Ehrhardt H, Schrembs D, Moritz C, Wachter F, Haldar S, Graubner U, Nathrath M, Jeremias I. Optimized anti-tumor effects of anthracyclines plus Vinca alkaloids using a novel, mechanism-based application schedule. Blood 2011; 118:6123 - 31; http://dx.doi.org/10.1182/blood-2010-02-269811; PMID: 21926351
   PubMed Web of Science ®Google Scholar
• Zeller WJ, Berger M, Schmähl D. Synergistic action of vincristine and adriamycin in the treatment of experimental rat leukemia L5222. Cancer Res 1979; 39:1071 - 3; PMID: 427748
   PubMed Web of Science ®Google Scholar
• Zimmermann GR, Lehár J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 2007; 12:34 - 42; http://dx.doi.org/10.1016/j.drudis.2006.11.008; PMID: 17198971
   PubMed Web of Science ®Google Scholar
• Dy GK, Adjei AA. Systemic cancer therapy: evolution over the last 60 years. Cancer 2008; 113:Suppl 1857 - 87; http://dx.doi.org/10.1002/cncr.23651; PMID: 18798529
   PubMedGoogle Scholar
• Ramaswamy S. Rational design of cancer-drug combinations. N Engl J Med 2007; 357:299 - 300; http://dx.doi.org/10.1056/NEJMcibr072593; PMID: 17634467
   PubMed Web of Science ®Google Scholar
• Frei E 3rd. Curative cancer chemotherapy. Cancer Res 1985; 45:6523 - 37; PMID: 2998603
   PubMed Web of Science ®Google Scholar
• Brozovic A, Osmak M. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett 2007; 251:1 - 16; http://dx.doi.org/10.1016/j.canlet.2006.10.007; PMID: 17125914
   PubMed Web of Science ®Google Scholar
• Fan M, Chambers TC. Role of mitogen-activated protein kinases in the response of tumor cells to chemotherapy. Drug Resist Updat 2001; 4:253 - 67; http://dx.doi.org/10.1054/drup.2001.0214; PMID: 11991680
   PubMed Web of Science ®Google Scholar
• Olson JM, Hallahan AR. p38 MAP kinase: a convergence point in cancer therapy. Trends Mol Med 2004; 10:125 - 9; http://dx.doi.org/10.1016/j.molmed.2004.01.007; PMID: 15102355
   PubMed Web of Science ®Google Scholar
• Sauter KA, Magun EA, Iordanov MS, Magun BE. ZAK is required for doxorubicin, a novel ribotoxic stressor, to induce SAPK activation and apoptosis in HaCaT cells. Cancer Biol Ther 2010; 10:258 - 66; http://dx.doi.org/10.4161/cbt.10.3.12367; PMID: 20559024
   PubMedGoogle Scholar
• Wong J, Smith LB, Magun EA, Engstrom T, Kelley-Howard K, Jandhyala DM, Thorpe CM, Magun BE, Wood LJ. Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of doxorubicin. Cancer Biol Ther 2013; 14:56 - 63; http://dx.doi.org/10.4161/cbt.22628; PMID: 23114643
   PubMed Web of Science ®Google Scholar
• Pétrilli V, Dostert C, Muruve DA, Tschopp J. The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol 2007; 19:615 - 22; http://dx.doi.org/10.1016/j.coi.2007.09.002; PMID: 17977705
   PubMed Web of Science ®Google Scholar
• Sutterwala FS, Ogura Y, Szczepanik M, Lara-Tejero M, Lichtenberger GS, Grant EP, Bertin J, Coyle AJ, Galán JE, Askenase PW, et al. Critical role for NALP3/CIAS1/Cryopyrin in innate and adaptive immunity through its regulation of caspase-1. Immunity 2006; 24:317 - 27; http://dx.doi.org/10.1016/j.immuni.2006.02.004; PMID: 16546100
   PubMed Web of Science ®Google Scholar
• Tsuchiya K, Hara H. The inflammasome and its regulation. Crit Rev Immunol 2014; 34:41 - 80; http://dx.doi.org/10.1615/CritRevImmunol.2013008686; PMID: 24579701
   PubMed Web of Science ®Google Scholar
• Vladimer GI, Marty-Roix R, Ghosh S, Weng D, Lien E. Inflammasomes and host defenses against bacterial infections. Curr Opin Microbiol 2013; 16:23 - 31; http://dx.doi.org/10.1016/j.mib.2012.11.008; PMID: 23318142
   PubMed Web of Science ®Google Scholar
• Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol 2013; 13:397 - 411; http://dx.doi.org/10.1038/nri3452; PMID: 23702978
   PubMed Web of Science ®Google Scholar
• Bruchard M, Mignot G, Derangère V, Chalmin F, Chevriaux A, Végran F, Boireau W, Simon B, Ryffel B, Connat JL, et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med 2013; 19:57 - 64; http://dx.doi.org/10.1038/nm.2999; PMID: 23202296
   PubMed Web of Science ®Google Scholar
• Sauter KA, Wood LJ, Wong J, Iordanov M, Magun BE. Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome. Cancer Biol Ther 2011; 11:1008 - 16; http://dx.doi.org/10.4161/cbt.11.12.15540; PMID: 21464611
   PubMed Web of Science ®Google Scholar
• Arend WP. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J Clin Invest 1991; 88:1445 - 51; http://dx.doi.org/10.1172/JCI115453; PMID: 1834696
   PubMed Web of Science ®Google Scholar
• Vyleta ML, Wong J, Magun BE. Suppression of ribosomal function triggers innate immune signaling through activation of the NLRP3 inflammasome. PLoS One 2012; 7:e36044; http://dx.doi.org/10.1371/journal.pone.0036044; PMID: 22606244
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 2006; 94:1765 - 9; http://dx.doi.org/10.1038/sj.bjc.6603170; PMID: 16721371
   PubMed Web of Science ®Google Scholar
• O’Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009; 16:401 - 12; http://dx.doi.org/10.1016/j.ccr.2009.09.028; PMID: 19878872
   PubMed Web of Science ®Google Scholar
• Ranieri G, Gadaleta-Caldarola G, Goffredo V, Patruno R, Mangia A, Rizzo A, Sciorsci RL, Gadaleta CD. Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development. Curr Med Chem 2012; 19:938 - 44; http://dx.doi.org/10.2174/092986712799320736; PMID: 22214462
   PubMed Web of Science ®Google Scholar
• Sutterwala FS, Ogura Y, Flavell RA. The inflammasome in pathogen recognition and inflammation. J Leukoc Biol 2007; 82:259 - 64; http://dx.doi.org/10.1189/jlb.1206755; PMID: 17470531
   PubMed Web of Science ®Google Scholar
• Gavegnano C, Detorio MA, Bassit L, Hurwitz SJ, North TW, Schinazi RF. Cellular pharmacology and potency of HIV-1 nucleoside analogs in primary human macrophages. Antimicrob Agents Chemother 2013; 57:1262 - 9; http://dx.doi.org/10.1128/AAC.02012-12; PMID: 23263005
   PubMed Web of Science ®Google Scholar
• Vĕtvicka V, Bilej M, Kincade PW. Resistance of macrophages to 5-fluorouracil treatment. Immunopharmacology 1990; 19:131 - 8; http://dx.doi.org/10.1016/0162-3109(90)90048-J; PMID: 2351535
   PubMed Web of Science ®Google Scholar
• Magnani M, Balestra E, Fraternale A, Aquaro S, Paiardini M, Cervasi B, Casabianca A, Garaci E, Perno CF. Drug-loaded red blood cell-mediated clearance of HIV-1 macrophage reservoir by selective inhibition of STAT1 expression. J Leukoc Biol 2003; 74:764 - 71; http://dx.doi.org/10.1189/jlb.0403156; PMID: 12960277
   PubMed Web of Science ®Google Scholar
• Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994; 12:141 - 79; http://dx.doi.org/10.1146/annurev.iy.12.040194.001041; PMID: 8011280
   PubMed Web of Science ®Google Scholar
• Liu SF, Malik AB. NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol 2006; 290:L622 - 45; http://dx.doi.org/10.1152/ajplung.00477.2005; PMID: 16531564
   PubMed Web of Science ®Google Scholar
• Zhou ZY, Wan LL, Yang QJ, Han YL, Li Y, Yu Q, Guo C, Li X. Evaluation of the pharmacokinetics and cardiotoxicity of doxorubicin in rat receiving nilotinib. Toxicol Appl Pharmacol 2013; 272:238 - 44; http://dx.doi.org/10.1016/j.taap.2013.06.002; PMID: 23770382
   PubMed Web of Science ®Google Scholar
• Villar VH, Vögler O, Martínez-Serra J, Ramos R, Calabuig-Fariñas S, Gutiérrez A, Barceló F, Martín-Broto J, Alemany R. Nilotinib counteracts P-glycoprotein-mediated multidrug resistance and synergizes the antitumoral effect of doxorubicin in soft tissue sarcomas. PLoS One 2012; 7:e37735; http://dx.doi.org/10.1371/journal.pone.0037735; PMID: 22662203
   PubMed Web of Science ®Google Scholar
• Shen T, Kuang YH, Ashby CR, Lei Y, Chen A, Zhou Y, Chen X, Tiwari AK, Hopper-Borge E, Ouyang J, et al. Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10). PLoS One 2009; 4:e7520; http://dx.doi.org/10.1371/journal.pone.0007520; PMID: 19841739
   PubMedGoogle Scholar
• Korcheva V, Wong J, Corless C, Iordanov M, Magun B. Administration of ricin induces a severe inflammatory response via nonredundant stimulation of ERK, JNK, and P38 MAPK and provides a mouse model of hemolytic uremic syndrome. Am J Pathol 2005; 166:323 - 39; http://dx.doi.org/10.1016/S0002-9440(10)62256-0; PMID: 15632024
   PubMed Web of Science ®Google Scholar